AIDS Clinical Trial Group Laboratory Center

艾滋病临床试验组实验室中心

• 批准号: 10527322
• 负责人: Grace M Aldrovandi
• 金额: $ 819.65万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-01-01 至 2027-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10527322
• 关键词: AIDS clinical trial group; Address; Affect; Area; Biological Assay; Biological Markers; Clinical; Clinical Research; Clinical Trials; Collaborations; DNA Repository; Data Coordinating Center; Disease remission; Evaluation; Genomics; HIV; HIV/AIDS; Health; Hepatitis B; Immunology; Infection; International; Intervention; Knowledge; Laboratories; Laboratory Research; Laboratory Study; Leadership; Measures; Morbidity - disease rate; Neurologic; Pathogenesis; Patients; Pharmacology; Population; Procedures; Protocols documentation; Research; Research Personnel; Research Priority; Research Support; Safety; Scientific Advances and Accomplishments; Site; Specimen; Standardization; Testing; Therapeutic; Total Quality Management; Training Programs; Training Support; Training and Education; Tuberculosis; United States National Institutes of Health; antiretroviral therapy; assay development; comorbidity; human DNA; improved; innovation; laboratory experience; mortality; new therapeutic target; novel; operation; programs; treatment guidelines; virology

ABSTRACT The AIDS Clinical Trials Group (ACTG) has been at the forefront of clinical research to advance HIV therapeutics and improve the health of patients living with HIV/AIDS for over 30 years. Rigorous scientific research conducted by the ACTG has laid the cornerstones for current HIV treatment guidelines. In this application for the competitive renewal of the ACTG Network Laboratory Center, we propose a transformative laboratory research agenda that draws on an international consortium of prominent clinical and laboratory investigators in collaboration with a world-class Statistical and Data Management Center to conduct leading edge laboratory research, testing, assay development and laboratory training for the support of innovative interventional clinical trials. The ACTG Network Laboratory Center will improve scientific knowledge and technical capability by providing state-of-the-art laboratory support in the four NIH/DAIDS priority areas: antiretroviral therapy (ART) free HIV remission, 2) novel therapeutics targeting HIV, 3) tuberculosis, and 4) HIV co-morbidities, including neurologic complications and hepatitis B cure. The continued expansion of an effective, quality-assured laboratory program at domestic and international sites for protocol safety measures, state-of-the-art assays for virology and tuberculosis, immunology and biomarkers, pharmacology, and genomics will provide the essential framework for advancing the scientific agenda of the ACTG Network. The Laboratory Center will continue to provide oversight of established specimen and human DNA repositories for the ACTG Network, harmonize specific laboratory testing and standardized operating procedures with other networks, where feasible, and support the laboratory training of technologists and investigators domestically and internationally.

摘要 艾滋病临床试验组（ACTG）一直处于临床研究的前沿， 艾滋病毒治疗和改善艾滋病毒/艾滋病患者的健康超过30年。 ACTG进行的严格科学研究为目前的艾滋病毒奠定了基础 治疗指南。在本申请中，ACTG网络的竞争性更新 实验室中心，我们提出了一个变革性的实验室研究议程，借鉴了 国际著名临床和实验室研究者联盟与 世界一流的统计和数据管理中心进行领先的实验室 研究、测试、分析开发和实验室培训，以支持创新 干预性临床试验。ACTG网络实验室中心将提高科学 知识和技术能力，在四个国家提供最先进的实验室支持， NIH/DAIDS优先领域：无抗逆转录病毒疗法（ART）的艾滋病毒缓解，2）新型疗法 针对艾滋病毒，3）结核病，和4）艾滋病毒合并症，包括神经系统并发症和 B型肝炎治愈。持续扩大一个有效的，质量有保证的实验室计划， 研究方案安全性措施的国内和国际研究中心， 病毒学和结核病，免疫学和生物标志物，药理学和基因组学将 为推进ACTG网络的科学议程提供基本框架。的 实验室中心将继续监督已建立的标本和人类DNA ACTG网络的存储库，协调特定的实验室测试和标准化 在可行的情况下，与其他网络一起制定操作程序，并支持实验室培训 技术专家和研究人员在国内和国际。